Chris Twelves

16.3k citations

183 papers · 9.7k indexed · 3 hit papers · h-index 47

Impact in

Oncology top 0.2%
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Colorectal Cancer Surgical Treatments
Cancer Research top 0.5%
- Breast Cancer Treatment Studies

Papers in

Oncology 145
- Cancer Treatment and Pharmacology 80
- Colorectal Cancer Treatments and Studies 57
- HER2/EGFR in Cancer Research 32
- Lung Cancer Research Studies 22
- Neutropenia and Cancer Infections 15
Cancer Research 41
- Breast Cancer Treatment Studies 20

Co-authors: Jim Cassidy Joyce O’Shaughnessy V J O'Neill B Osterwalder Eric Van Cutsem J Cassidy Guy van Hazel P. Fumoleau
Journals: Journal of Clinical Oncology (36 papers)British Journal of Cancer (20 papers)Annals of Oncology (18 papers)European Journal of Cancer (17 papers)Cancer Chemotherapy and Pharmacology (10 papers)
Partner nations: United Kingdom United States Spain

In The Last Decade

Chris Twelves

180 papers receiving 9.4k citations

Hit Papers

align trajectories log scale

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study 2011 · 807 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2011 The Lancet
2002 Journal of Clinical Oncology
1999 PubMed

Peers

Countries citing papers authored by Chris Twelves

Since Specialization

Citations

This map shows the geographic impact of Chris Twelves's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Twelves with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Twelves more than expected).

Fields of papers citing papers by Chris Twelves

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Twelves. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Twelves. The network helps show where Chris Twelves may publish in the future.

Co-authors

The 25 scholars most cited alongside Chris Twelves, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Chris Twelves Line = papers co-authored together Chris Twelves links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study Breast Cancer Research and Treatment ·Mark Axelrod, Stefan N. Symeonides, Duncan Wheatley, Stephen Chan, Adrian Murray Brunt, Karen McAdam, Peter Schmid, Simon Waters, Christopher Poole, Chris Twelves, Timothy Perren, John M.S. Bartlett, Tammy Piper, T. Hosni, Michelle Welsh, Robert Hill, Lisa Hopcroft, Peter Barrett‐Lee, David Cameron	2023	8
2	Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial The Lancet Oncology ·Sacha J. Howell, Angela Casbard, Margherita Carucci, Kate Ingarfield, Rachel Butler, Siân Morgan, Ajit Dhake, C. Bale, Pavel Bezecny, 袁春生, Chris Twelves, Ramachandran Venkitaraman, Simon Waters, Elza C. de Bruin, Gaia Schiavon, Andrew Foxley, Robert H. Jones	2022	87
3	Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis Scientific Reports ·Joyce O’Shaughnessy, Javier Cortés, Chris Twelves, Lori J. Goldstein, Karenza Alexis, Ran Xie, Carlos H. Barrios, Takayuki Ueno	2020	8
4	CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial Trials ·Rob Coleman, Janet E. Brown, Emma Rathbone, Louise Flanagan, Amirmohammad Mirzaei, Fred Goebel, Sacha J. Howell, Chris Twelves, Carlo Palmieri, Anjana Anand, Iain R. Macpherson, Sarah Brown	2020	11
5	Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol Clinical Cancer Research ·Hope S. Rugo, Javier Cortés, Ahmad Awada, Joyce O’Shaughnessy, Chris Twelves, Seock‐Ah Im, Alison L. Hannah, Lin Lü, Sherwin K. B. Sy, Volkan Selçuk, Deborah A. Zajchowski, Darren W. Davis, Mary Tagliaferri, Ute Hoch, Edith A. Perez	2018	17
6	Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial Breast Cancer Research and Treatment ·Javier Cortés, Hope S. Rugo, Ahmad Awada, Chris Twelves, Edith A. Perez, Seock‐Ah Im, أشواق تريعة, Lee S. Schwartzberg, Véronique Dièras, Denise A. Yardley, David A. Potter, Audrey Mailliez, Alvaro Moreno‐Aspitia, Jin-Seok Ahn, Carol Zhao, Ute Hoch, Mary Tagliaferri, Alison L. Hannah, Joyce O’Shaughnessy	2017	36
7	First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer Clinical Cancer Research ·Sarah P. Blagden, Arieli Maciel Palacio Alvarez, Debra H. Josephs, Chara Stavraka, Andrea Zivi, David J. Pinato, Alan Anthoney, Shaun Decordova, Karen E. Swales, Ruth Riisnaes, Lorna Pope, Kohei Noguchi, Marco Vettori, 敬井出上, F. Montessoro, Keith Jones, Chris Twelves, James Spicer, Udai Banerji	2014	36
8	Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer Annals of Oncology ·Chris Twelves, Ewa Chmielowska, Libor Havel, Sanjay Popat, Anna Świeboda-Sadlej, Piotr Sawrycki, Paul Bycott, Antonella Ingrosso, S. Kim, James A. Williams, C. Chen, Anthony J. Olszanski, Pietro De Besi, Joan H. Schiller	2013	30
9	Effects of Tasisulam Sodium on the Pharmacokinetics of Tolbutamide in Patients with Advanced Solid Tumours Annals of Oncology ·Chris Twelves, RajKumar Nagpal, Alan Anthoney, Jill Chappell, Putu Ayu Paramita Dharmayanti, Х. Х. Хамидулина, Rebecca Kristeleit	2013	1
10	Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients Annals of Oncology ·Jim Cassidy, Leonard B. Saltz, Chris Twelves, Eric Van Cutsem, Paulo M. Hoff, Yoon‐Koo Kang, 勝昭滝野, Frank Gilberg, David Cunningham	2011	70
11	The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib Cancer Chemotherapy and Pharmacology ·Jiří Horák, Jeff White, Adrian L. Harris, Mark Verrill, James Carmichael, A. Belgour, Mireille Cantarini, M. Macpherson, Alan Swaisland, Helen Swaisland, Chris Twelves	2011	25
12	Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients Clinical Cancer Research ·Liane M. McGlynn, Tove Kirkegaard, Joanne Edwards, Sian Tovey, David Cameron, Chris Twelves, John M.S. Bartlett, Timothy G. Cooke	2009	70
13	Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study Clinical Cancer Research ·Mark R. Albertella, Paul M. Loadman, Philip H. Jones, Roger M. Phillips, R. Rampling, N.G. Burnet, H. Peng, Alan Anthoney, Egils Vjaters, Chris R. Dunk, Peter A. Harris, Alvin Wong, Alshad S. Lalani, Chris Twelves	2008	98
14	Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial Journal of Clinical Oncology ·John M.S. Bartlett, Alison F. Munro, David Cameron, Jeremy Thomas, R.J. Prescott, Chris Twelves	2008	67
15	Maximum a posteriori Bayesian estimation of epirubicin clearance by limited sampling British Journal of Clinical Pharmacology ·S. Tuchiya, Alison H. Thomson, Nicola Dobbs, Chris Twelves	2004	3
16	A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer Annals of Oncology ·Helen Mackay, Mark Hill, Chris Twelves, Rosalind Glasspool, Timothy Price, 筧善行, Alison Massey, Andréa do Nascimento Sant'Anna, Geovania Nascimento Costa, A. H. Zhou, Christophe Martin, David Cunningham	2003	28
17	Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial Annals of Oncology ·Werner Scheithauer, J McKendrick, S. Begbie, Markus Borner, W. Ivon Burns, Howard A. Burris, Jim Cassidy, Duncan I. Jodrell, P. Koralewski, E.L. Levine, Norbert Marschner, Jean A. Maroun, Pilar García‐Alfonso, Jerzy Tujakowski, Guy van Hazel, A. Wong, J. Załuski, Chris Twelves	2003	222
18	A Pilot Study of Continuous Infusional 5-Fluorouracil, Doxorubicin and Cyclophosphamide in Breast Cancer Clinical Oncology ·Helen Mackay, D. Bissett, Chris Twelves, P. Vasey	1999	1
19	Activity of Doxorubicin Covalently Bound to a Novel Human Serum Albumin Microcapsule Investigational New Drugs ·Martin Eatock, João M. G. Caraça, Christoph von Fürer-Haimendore, Wilson J. Angerson, Colin S. McArdle, Francesca Ellis, Chris Twelves	1999	13
20	A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion British Journal of Cancer ·Luis Paz‐Ares, Robert L. Kunka, Phillip Stokes, J Cassidy, 文昭松永, P.A. Beranek, S.B. Kaye, Eun-Kyoung Hahm, Eddy Wibowo, Brigitte unter Mitarbeit von Röder, Paul Wissel, Chris Twelves, Peter J. O’Dwyer	1998	20

About Chris Twelves

Chris Twelves is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Dermatology and Pathology and Forensic Medicine, having authored 183 papers that have together received 9.7k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (80 papers), Colorectal Cancer Treatments and Studies (57 papers), HER2/EGFR in Cancer Research (32 papers), Lung Cancer Research Studies (22 papers), Breast Cancer Treatment Studies (20 papers), Advanced Breast Cancer Therapies (19 papers), Cancer therapeutics and mechanisms (17 papers) and Neutropenia and Cancer Infections (15 papers). The work is most often cited by research in Oncology (6.5k citations), Cancer Research (1.7k citations), Dermatology (762 citations), Pulmonary and Respiratory Medicine (2.3k citations) and Family Practice (143 citations). Chris Twelves has collaborated with scholars based in United Kingdom, United States and Spain. Frequent co-authors include Jim Cassidy, Joyce O’Shaughnessy, V J O'Neill, B Osterwalder, Eric Van Cutsem, J Cassidy, Guy van Hazel, P. Fumoleau, Robert Leonard and Svetislava J. Vukelja. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Cancer, Annals of Oncology, European Journal of Cancer and Cancer Chemotherapy and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact